References
- GBD 2015 Disease and Injury Incidence and Prevalence CollaboratorsDisease and Injury Incidence and Prevalence, Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2016Lancet2016388100531545160227733282
- SmolenJSAletahaDMcinnesIBRheumatoid arthritisLancet2016388100552023203827156434
- SmolenJSAletahaDKoellerMWeismanMHEmeryPNew therapies for treatment of rheumatoid arthritisLancet200737096021861187417570481
- van der KooijSMde Vries-BouwstraJKGoekoop-RuitermanYPPatient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritisArthritis Rheum200961141219116965
- AvciABFeistEBurmesterGRBiologicals in rheumatoid arthritis: current and futureRMD Open201511e00012726535144
- CurtisJRSinghJAUse of biologics in rheumatoid arthritis: current and emerging paradigms of careClin Ther201133667970721704234
- StrandVSinghJAImproved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trialsAm J Manag Care200713Suppl 9S237S25118095787
- SinghJAChristensenRWellsGAA network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCMAJ20091811178779619884297
- PutrikPRamiroSKvienTKInequities in access to biologic and synthetic DMARDs across 46 European countriesAnn Rheum Dis201473119820623467636
- SchiestlMZabranskyMSörgelFTen years of biosimilars in Europe: development and evolution of the regulatory pathwaysDrug Des Devel Ther20171115091515
- Generics and Biosimilars InitiativeBiosimilars of etanercept2017 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-of-etanerceptAccessed July 1, 2018
- Generics and Biosimilars InitiativeBiosimilars of adalimumab2018 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-of-adalimumabAccessed July 1, 2018
- KivitzACohenSDowdJEClinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trialClin Ther200628101619162917157117
- DemaryWSchwenkeHRockwitzKSubcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experiencePatient Prefer Adherence201481061107125125973
- Borrás-BlascoJGracia-PérezARosique-RoblesJDCasteráMDAbadFJAcceptability of switching adalimumab from a prefilled syringe to an autoinjection penExpert Opin Biol Ther201010330130720059372
- KivitzASeguradoOGHumira pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumabExpert Rev Med Devices20074210911617359217
- van den BemtBJZwikkerHEvan den EndeCHMedication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literatureExpert Rev Clin Immunol20128433735122607180
- ThakurKBibergerAHandrichARezkMFPerceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: a new European Union-approved etanercept biosimilar (Benepali) versus etanercept (Enbrel) – findings from a nurse survey in EuropeRheumatol Ther201631778927747519
- ThakurKBibergerAHandrichARezkMFPatient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in EuropeRheumatol Ther20163224525627817152
- EgethMSoosaarJNashPPatient and healthcare professionals preference for Brenzys vs. Enbrel autoinjector for rheumatoid arthritis: a randomized crossover simulated-use studyAdv Ther20173451157117228417318